Q-omics provides the consensus-scored NBEAL2 profile across patient tissues and cancer cell-line models. NBEAL2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NBEAL2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, NBEAL2 protein abundance shows 22,094 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, COAD, and GBM as cancer lineages where NBEAL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBEAL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBEAL2 survival associations across molecular data types. NBEAL2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBEAL2 RNA expression–survival associations across cancer types. High NBEAL2 expression shows unfavorable associations in ACC, LGG, THCA and LIHC, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for NBEAL2 RNA expression.
This table summarizes NBEAL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NBEAL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBEAL2 shows lower tumor expression in HNSC and KIRC and higher tumor expression in COAD, BLCA, LIHC and UCEC. The COAD box plot shows higher NBEAL2 RNA expression in tumor versus normal tissue (log2 FC = +1.761, t-test p < 0.001).
This table shows molecular features associated with NBEAL2 in patient tissues and cancer cell lines. In patient samples, NBEAL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NBEAL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
